Duchenne Muscular Dystrophy
PDL Reference Documents
PDL Status Values
Y = preferred
N = non-preferred. Non-preferred drugs listed as N but without clinical drug use criteria are subject to the
Non-Preferred Drugs in Select PDL Classes prior authorization criteria.
New drugs will be listed as N until reviewed by the P&T Committee and are subject to the
New Drug Policy.
V = voluntary non-preferred. Non-preferred mental health drugs are listed as V and prior authorization is not required.
Null (i.e. blank) = indicates the class or specific drug has not been reviewed for PDL placement.
To request a Prior Authorization, please use this form.
| Generic Name | Brand Name | Form | PDL Status |
Current Drug Use Criteria | New Drug Evaluation |
|---|---|---|---|---|---|
| casimersen | AMONDYS-45 | VIAL | N | PA Document | Aug 05, 2021 |
| deflazacort | EMFLAZA | ORAL SUSP | N | PA Document | |
| deflazacort | DEFLAZACORT | TABLET | N | PA Document | |
| deflazacort | EMFLAZA | TABLET | N | PA Document | Jul 27, 2017 |
| delandistrogene moxeparvc-rokl | ELEVIDYS | KIT | N | PA Document | |
| delandistrogene moxeparvc-rokl | ELEVIDYS | VIAL | N | PA Document | |
| eteplirsen | EXONDYS-51 | VIAL | N | PA Document | Jul 27, 2017 |
| golodirsen | VYONDYS-53 | VIAL | N | PA Document | |
| vamorolone | AGAMREE | ORAL SUSP | N | PA Document | |
| viltolarsen | VILTEPSO | VIAL | N | PA Document |